- $30.75bn
- $58.97bn
- CA$24.67bn
- 74
- 73
- 59
- 77
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23,793 | 22,883 | 23,449 | 24,174 | 24,673 |
Cost of Revenue | |||||
Gross Profit | 16,437 | 15,916 | 16,159 | 16,533 | 16,747 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18,365 | 18,318 | 18,624 | 19,089 | 19,518 |
Operating Profit | 5,428 | 4,565 | 4,825 | 5,085 | 5,155 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,353 | 3,265 | 3,936 | 3,893 | 3,323 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,224 | 2,473 | 2,892 | 2,926 | 2,327 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 3,191 | 2,634 | 2,840 | 2,868 | 2,263 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,040 | 2,498 | 2,709 | 2,716 | 2,076 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.54 | 3.12 | 3.38 | 3.32 | 2.53 |
Dividends per Share |